A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir has not been determined. Therefore, we conducted a Phase Ia study to establish the maximum tolerated dose (MTD) and dose limiting toxicities...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Blumenthal, Gideon M., Gills, Joell J., Ballas, Marc S., Bernstein, Wendy B., Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M., LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R., Figg, William D., Dennis, Phillip A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226674/
https://ncbi.nlm.nih.gov/pubmed/25327558
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados